Published: 2019 November 18
Updated : 2022 November 03

Acute Lung Injury Market

SKU : PH2175
180 pages
Report Summary
Table of Contents
List of Tables & Figures

Acute Lung Injury Market is Segment By Therapy (Mechanical ventilation, Pharmacotherapy, Fluid management), By End-user (Hospitals, Clinics,Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Acute Lung Injury Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.8% during the forecast period (2022-2029).

Acute Lung Injury Market



Market CAGR


Segments Covered

By Therapy, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Acute lung injury is a severe condition caused by acute hypoxemic respiratory failure. It is a crucial source of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary edema. Symptoms seen in acute lung injury include severe shortness of breath, confusion, low blood pressure, and extreme tiredness.

Market Dynamics

The major driving forces are the growing prevalence of lung-related diseases, the increase in the geriatric population, the growth in awareness about health diagnostics, and technological advancements.

The rising prevalence of pulmonary diseases is expected to drive market growth.

The growing prevalence of pulmonary diseases is driving the global acute pulmonary injury market. For instance, according to the World Bank population projections and Global Burden of Disease data for COPD from 39 countries in Europe in 2020, it is estimated that there were 36,580,965 Europeans with COPD. In 2050, it is projected that 49,453,852 people will have COPD (prevalence=9.3%), accounting for a 35.2% relative increase in patients and a 39.6% increase in prevalence. Moreover, According to Global Initiative For Asthma 2022 report, Asthma affects an estimated 300 million individuals worldwide, and Approximately 96% of asthma deaths are in low- and middle-income countries. Furthermore, the increased tobacco usage is fueling the acute lung injury market. For instance, as per the data from WHO, in 2020, 22.3% of the global population used Tobacco, 36.7% of all men and 7.8% of the world's women; Tobacco kills more than 8 million people each year. More than 7 million deaths result from direct tobacco use, while around 1.2 million are from non-smokers exposed to second-hand smoke. Over 80% of the world's 1.3 billion tobacco users live in low- and middle-income countries.

The complications associated with the therapies and the high cost are expected to hinder global acute lung injury market growth.

However, the complications associated with the therapies, high cost of therapies, low adoption rate of digital radiography and the portable spirometers for diagnosing the condition impede the market growth. The complications associated with the therapies are likely to hamper the market growth. For instance, Mechanical ventilation is often a life-saving intervention but carries potential complications, including pneumothorax, alveolar damage, ventilator-associated pneumonia, airway injury, and ventilator-associated tracheobronchitis.

Industry analysis.

The global acute lung injury market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, and pipeline analysis.

Segment Analysis

The mechanical ventilation segment is expected to dominate the acute lung injury market throughout the forecast period (2022-2029).

The mechanical ventilation segment is expected to grow at a high rate over the forecast period (2022-2029), as it is the primary choice for the supportive treatment of patients with acute lung injury (ALI). It includes the delivery of air/oxygen at tidal volumes and frequencies to be enough to reduce the pressure on breathing with simultaneous progress in oxygenation. If a patient requires prolonged mechanical ventilation, the tracheotomy process is suggested that permits a stable airway, mobilization, and ease out the deterring of mechanical ventilation. Extracorporeal membrane oxygenation (ECMO) is not used extensively, but it is in function in some instances.

Geographical Analysis

The North American region holds the largest market share of the global acute lung injury market.

North America is dominating the global acute lung injury market in 2021 and is estimated to hold a significant market size over the forecast period (2022-2029). For instance, according to the Asthma And Allergy Foundation of America, Approximately 25 million people in the U.S. have asthma. On average, 11 people in the U.S. die from asthma each day. In 2020, 4,145 people died from asthma. Furthermore, America's high number of cigarette smokers is fueling its dominance over the global market. For instance, according to the Pan American Health Organization, in the American region, there are around 142 million tobacco users and around 127 million smokers; every year, 1 million people die from smoking. In addition, as per CDC, e-cigarette, or vaping, product use-associated lung injury (EVALI) in February 2020, a total of 2,807 hospitalized EVALI cases or deaths have been reported to CDC from all 50 states, the District of Columbia, and two U.S. territories making it an EVALI outbreak in America.

Competitive Landscape

The key players operating in the global acute lung injury market are Altor BioScience Corporation, GlaxoSmithKline Plc, Gilead Sciences Inc., Commence Bio, Inc., CompleGen, Inc., Histocell S.L., Windtree Therapeutics, Inc., Navigen Pharmaceuticals, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., and Ono Pharmaceutical Co., Ltd. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the acute lung injury market globally. For instance, on 16 August 2022, GSK acquired Affinivax, Inc.

Gilead Sciences Inc.


Gilead Sciences Inc. is an American biopharmaceutical founded in 1987 in California, United States and focused on researching and developing antiviral drugs used to treat HIV/AIDS, hepatitis B & C, Influenza, and COVID-19.

Product Portfolio:

 Gilead Sciences Inc.’s product portfolio for acute lung injury has Cayston (Aztreonam for inhalation solution) and Tamiflu (Oseltamivir Phosphate).

The global acute lung injury market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.


Frequently Asked Questions

What is the Projected CAGR value of the Acute Lung Injury Market?

Acute Lung Injury Market is expected to grow at a CAGR of 5.8% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Acute Lung Injury Market during 2022-2029.

Which is the fastest growing region in the Acute Lung Injury Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period.

Trending Topics

Lung Cancer Surgery Market

Portable Lung Monitors Market

Airway Stent/Lung Stent Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy